Scott Chih-Hsi Kuo

19PUBLICATIONS
49CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jun 29, 2026
Clinical characteristics and outcomes of advanced EGFR-mutated NSCLC treated with 45 or 30 mg starting doses of dacomitinib: a retrospective multicenter analysis.

|Jun 06, 2024
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous <i>EGFR</i>-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.

D Ross Camidge, Jair Bar, Hidehito Horinouchi

|May 25, 2024
A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer.

Ping-Chih Hsu, Bing-Chen Wu, Chin-Chou Wang

|Jan 27, 2024
Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer.

Li-Chung Chiu, Ping-Chih Hsu, Chin-Chou Wang

|Jan 22, 2024
Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC.

Pi-Hung Tung, Tzu-Hsuan Chiu, Allen Chung-Cheng Huang

|Mar 30, 2023
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers.

Julia Rotow, Jyoti D Patel, Matthew P Hanley

Pageof 4

Frequent Collaborators

11 joint publications

Ping-Chih Hsu

4 joint publications

How-Wen Ko

4 joint publications

Li-Chung Chiu

4 joint publications

Cheng-Ta Yang